Table 2.
Predictor variables of adalimumab persistence at 24 months.
| Clinical characteristics | Adalimumab treatment | P-value | |
|---|---|---|---|
| Discontinuing (N = 111) | Continuing (N = 313) | ||
| General | |||
| Female patients, n (%) | 38 (34.2) | 159 (50.8) | 0.004 |
| Age (years) | 47.9 ± 13.1 | 48.4 ± 12.7 | 0.69 |
| BMI (Kg/M2) | 25.4 ± 4.5 | 25.9 ± 4.3 | 0.19 |
| Current smoker, n (%) | 24 (27) | 60 (20.5) | 0.26 |
| Arthritis assessment | |||
| Tender joint count | 7.3 ± 6 | 7 ± 5.7 | 0.93 |
| Swollen joint count | 2.6 ± 2.8 | 2.7 ± 2.8 | 0.71 |
| CRP (mg/dl) | 3.2 ± 5.3 | 3.8 ± 6.3 | 0.047 |
| DAPSA | 24.7 ± 9.8 | 25.5 ± 10.9 | 0.61 |
| Enthesitis | 54 (48.6) | 148 (47.3) | 0.89 |
| Dactylitis | 21 (19.1) | 87 (27.8) | 0.09 |
| Skin assessment | |||
| PASI | 4.4 ± 4.3 | 5.3 ± 5.7 | 0.63 |
| Comorbidities*, n (%) | |||
| Hypertension | 31 (28.2) | 99 (31.7) | 0.57 |
| Metabolic syndrome | 19 (17.6) | 56 (17.9) | 1.0 |
| Depression | 12 (11.1) | 26 (8.5) | 0.53 |
| Hyperuricemia | 4 (3.7) | 28 (9.1) | 0.12 |
| Cardiovascular disease | 7 (6.5) | 21 (6.8) | 1.0 |
| Uveitis | 7 (6.4) | 20 (6.4) | 1.0 |
| Crohn's disease | 4 (3.6) | 19 (6.1) | 0.47 |
| Ulcerative colitis | 3 (2.7) | 9 (2.9) | 1.0 |
| Medication, n (%) | |||
| Biologic naïve | 74 (66.7) | 217 (69.3) | 0.69 |
| Adalimumab | |||
| Monotherapy | 48 (43.2) | 142 (45.4) | 0.46 |
| Plus methotrexate | 46 (41.4) | 137 (43.8) | |
| Plus other DMARD | 17 (15.3) | 34 (10.9) | |
Data are presented as mean ± SD or number (%). N refers to number of patients treated with adalimumab for 24 months. BMI, body mass index; CRP, C-reactive protein; DAPSA, disease activity in psoriatic arthritis; DMARD, disease-modifying anti-rheumatic drugs; PASI, psoriasis area severity index; PsA, psoriatic arthritis.*including extra-articular manifestations. Comparisons in variables between patients discontinuing vs. those continuing adalimumab treatment at 24 months were performed using the Chi-squared test for categorical variables or the Mann-Whitney U-Test for non-parametric continuous variables. P-values reporting statistically significant differences are highlighted in bold.